Tom Greene

121.7k total citations · 21 hit papers
481 papers, 81.4k citations indexed

About

Tom Greene is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Tom Greene has authored 481 papers receiving a total of 81.4k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Nephrology, 93 papers in Cardiology and Cardiovascular Medicine and 60 papers in Surgery. Recurrent topics in Tom Greene's work include Dialysis and Renal Disease Management (144 papers), Chronic Kidney Disease and Diabetes (99 papers) and Blood Pressure and Hypertension Studies (64 papers). Tom Greene is often cited by papers focused on Dialysis and Renal Disease Management (144 papers), Chronic Kidney Disease and Diabetes (99 papers) and Blood Pressure and Hypertension Studies (64 papers). Tom Greene collaborates with scholars based in United States, Canada and Netherlands. Tom Greene's co-authors include Andrew S. Levey, Josef Coresh, John W. Kusek, Lesley A. Stevens, Frederick Van Lente, Yaping Zhang, Christopher H. Schmid, Harold I. Feldman, Julia B. Lewis and Paul W. Eggers and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Tom Greene

469 papers receiving 79.6k citations

Hit Papers

A New Equation to Estimate Glomerular Filtration Rate 1997 2026 2006 2016 2009 1999 2006 2020 2012 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A New Equation to Estimate Glomerular Filtration Rate
    2009 19.4k citations Andrew S. Levey, Lesley A. Stevens et al. Annals of Internal Medicine profile →
  2. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
    1999 12.6k citations Andrew S. Levey, Julia B. Lewis et al. Annals of Internal Medicine profile →
  3. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate
    2006 4.7k citations Andrew S. Levey, Josef Coresh et al. Annals of Internal Medicine profile →
  4. Dapagliflozin in Patients with Chronic Kidney Disease
    2020 3.0k citations Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. New England Journal of Medicine profile →
  5. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
    2012 3.0k citations Lesley A. Inker, Christopher H. Schmid et al. New England Journal of Medicine profile →
  6. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
    2006 2.3k citations Lesley A. Stevens, Josef Coresh et al. New England Journal of Medicine profile →
  7. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey
    2002 2.2k citations Josef Coresh, Tom Greene et al. American Journal of Kidney Diseases profile →
  8. Low-Level Environmental Lead Exposure and Children’s Intellectual Function: An International Pooled Analysis
    2005 1.7k citations Tom Greene et al. profile →
  9. Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values
    2007 1.5k citations Andrew S. Levey, Josef Coresh et al. profile →
  10. Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
    2002 1.3k citations Gerald J. Beck, Alfred K. Cheung et al. New England Journal of Medicine profile →
  11. Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD
    2008 811 citations Lesley A. Stevens, Josef Coresh et al. American Journal of Kidney Diseases profile →
  12. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate
    2002 584 citations Josef Coresh, John W. Kusek et al. American Journal of Kidney Diseases profile →
  13. Factors other than glomerular filtration rate affect serum cystatin C levels
    2009 576 citations Lesley A. Stevens, Christopher H. Schmid et al. profile →
  14. Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis
    2008 568 citations Gerald J. Beck, Tom Greene et al. profile →
  15. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study
    1997 549 citations Tom Greene, John W. Kusek et al. profile →
  16. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations in the Estimation of GFR in Health and in Chronic Kidney Disease
    2004 528 citations Emilio D. Poggio, Xuelei Wang et al. Journal of the American Society of Nephrology profile →
  17. Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2
    2010 454 citations Lesley A. Stevens, Christopher H. Schmid et al. American Journal of Kidney Diseases profile →
  18. GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
    2014 389 citations Andrew S. Levey, Lesley A. Inker et al. American Journal of Kidney Diseases profile →
  19. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology profile →
  20. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
    2019 314 citations Andrew S. Levey, Josef Coresh et al. American Journal of Kidney Diseases profile →
  21. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    2021 237 citations David C. Wheeler, Robert D. Toto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tom Greene United States 100 39.1k 17.9k 12.6k 12.4k 11.4k 481 81.4k
Glenn M. Chertow United States 121 42.7k 1.1× 11.6k 0.6× 12.2k 1.0× 9.9k 0.8× 7.8k 0.7× 814 69.5k
Giuseppe Remuzzi Italy 144 37.4k 1.0× 17.9k 1.0× 12.4k 1.0× 11.0k 0.9× 11.6k 1.0× 1.3k 95.1k
John W. Kusek United States 93 27.7k 0.7× 13.0k 0.7× 9.2k 0.7× 9.6k 0.8× 6.7k 0.6× 368 60.3k
Josef Coresh United States 133 50.9k 1.3× 30.8k 1.7× 16.1k 1.3× 16.2k 1.3× 16.9k 1.5× 952 116.0k
Andrew S. Levey United States 130 65.8k 1.7× 30.9k 1.7× 17.8k 1.4× 20.0k 1.6× 13.6k 1.2× 514 125.4k
Rinaldo Bellomo Australia 134 38.0k 1.0× 12.8k 0.7× 22.9k 1.8× 14.6k 1.2× 5.2k 0.5× 1.6k 99.8k
Kamyar Kalantar‐Zadeh United States 121 30.6k 0.8× 6.8k 0.4× 8.5k 0.7× 6.1k 0.5× 5.7k 0.5× 916 52.3k
George L. Bakris United States 116 12.1k 0.3× 35.6k 2.0× 10.8k 0.9× 10.8k 0.9× 25.6k 2.2× 849 68.8k
Harold I. Feldman United States 74 18.2k 0.5× 8.9k 0.5× 6.3k 0.5× 7.0k 0.6× 4.6k 0.4× 325 42.3k
Eberhard Ritz Germany 97 19.5k 0.5× 13.8k 0.8× 6.2k 0.5× 6.9k 0.6× 9.4k 0.8× 934 44.8k

Countries citing papers authored by Tom Greene

Since Specialization
Citations

This map shows the geographic impact of Tom Greene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Greene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Greene more than expected).

Fields of papers citing papers by Tom Greene

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Greene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Greene. The network helps show where Tom Greene may publish in the future.

Co-authorship network of co-authors of Tom Greene

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Greene. A scholar is included among the top collaborators of Tom Greene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Greene. Tom Greene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Derington, Catherine G., Guo Wei, Ravinder Singh, et al.. (2025). Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Network Open. 8(10). e2537297–e2537297.
2.
Shen, Jincheng, Ravinder Singh, Guo Wei, et al.. (2025). Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes. Diabetes Obesity and Metabolism. 27(4). 2120–2130. 2 indexed citations
3.
Jacobs, Joshua A., Catherine G. Derington, Alexander R. Zheutlin, et al.. (2024). Association Between Self‐Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Journal of the American Heart Association. 13(3). e031574–e031574. 3 indexed citations
4.
Nee, Robert, et al.. (2024). Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of CKD. Journal of the American Society of Nephrology. 35(3). 299–310. 3 indexed citations
5.
Ku, Elaine, Lesley A. Inker, Hocine Tighiouart, et al.. (2024). Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease. Annals of Internal Medicine. 177(7). 953–963. 14 indexed citations
6.
Derington, Catherine G., Adam P. Bress, Jennifer S. Herrick, et al.. (2023). Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults. American Journal of Hypertension. 36(9). 498–508. 5 indexed citations
7.
Nelson, Richard E., Thomas Byrne, Susan Zickmund, et al.. (2022). Which veterans in the Supportive Services for Veteran Families program receive temporary financial assistance and why: a mixed methods study. Journal of Social Distress and the Homeless. 32(2). 210–222. 4 indexed citations
8.
Jongs, Niels, Tom Greene, Glenn M. Chertow, et al.. (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. 9(11). 755–766. 126 indexed citations
9.
Fritz, Julie M., Daniel I. Rhon, Jacob Kean, et al.. (2020). A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol. Pain Medicine. 21(Supplement_2). S73–S82. 19 indexed citations
10.
11.
Heerspink, Hiddo J.L., Bergur V. Stefánsson, Ricardo Correa‐Rotter, et al.. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 383(15). 1436–1446. 3050 indexed citations breakdown →
12.
Brown, Samuel M., Ithan D. Peltan, Lindsay Leither, et al.. (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. Annals of the American Thoracic Society. 18(4). 590–597. 20 indexed citations
13.
14.
Voelker, James R., Paul H. Berg, Matthew J. Sheetz, et al.. (2016). Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. Journal of the American Society of Nephrology. 28(3). 953–962. 213 indexed citations
15.
Jones, Barbara, Brian C. Sauer, Makoto Jones, et al.. (2015). Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population. Annals of Internal Medicine. 1 indexed citations
16.
Li, Liang & Tom Greene. (2013). A Weighting Analogue to Pair Matching in Propensity Score Analysis. The International Journal of Biostatistics. 9(2). 215–234. 251 indexed citations
17.
Greene, Tom, Marshall M. Joffe, Bo Hu, Liang Li, & Kenneth M. Boucher. (2013). The Balanced Survivor Average Causal Effect. The International Journal of Biostatistics. 9(2). 291–306. 5 indexed citations
18.
Chan, Christopher T., Tom Greene, Glenn M. Chertow, et al.. (2013). Effects of Frequent Hemodialysis on Ventricular Volumes and Left Ventricular Remodeling. Clinical Journal of the American Society of Nephrology. 8(12). 2106–2116. 56 indexed citations
19.
Stevens, Lesley A., Josef Coresh, Christopher H. Schmid, et al.. (2008). Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD. American Journal of Kidney Diseases. 51(3). 395–406. 811 indexed citations breakdown →
20.
Poggio, Emilio D., Patrick Nef, Xuelei Wang, et al.. (2005). Performance of the Cockcroft-Gault and Modification of Diet in Renal Disease Equations in Estimating GFR in Ill Hospitalized Patients. American Journal of Kidney Diseases. 46(2). 242–252. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Glenn M. Chertow Breakdown of academic impact, for papers by Giuseppe Remuzzi Breakdown of academic impact, for papers by John W. Kusek Breakdown of academic impact, for papers by Josef Coresh Breakdown of academic impact, for papers by Andrew S. Levey Breakdown of academic impact, for papers by Rinaldo Bellomo Breakdown of academic impact, for papers by Kamyar Kalantar‐Zadeh Breakdown of academic impact, for papers by George L. Bakris Breakdown of academic impact, for papers by Harold I. Feldman Breakdown of academic impact, for papers by Eberhard Ritz
Rankless by CCL
2026